Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer’s disease: study protocol for a randomised controlled trial (ELAD study)

[1]  J. Buse,et al.  Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial , 2018, Annals of Internal Medicine.

[2]  R. McIntyre,et al.  Comparative efficacy and acceptability of antidiabetic agents for Alzheimer's disease and mild cognitive impairment: A systematic review and network meta‐analysis , 2018, Diabetes, obesity & metabolism.

[3]  Lijuan Wu,et al.  Subcutaneous administration of liraglutide ameliorates learning and memory impairment by modulating tau hyperphosphorylation via the glycogen synthase kinase-3β pathway in an amyloid β protein induced alzheimer disease mouse model. , 2016, European journal of pharmacology.

[4]  A. Gjedde,et al.  In Alzheimer’s Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial , 2016, Front. Aging Neurosci..

[5]  A. Flint,et al.  Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics , 2015, Clinical Pharmacokinetics.

[6]  M. Prince,et al.  World Alzheimer Report 2015 - The Global Impact of Dementia: An analysis of prevalence, incidence, cost and trends , 2015 .

[7]  J. Cummings,et al.  Alzheimer’s disease drug-development pipeline: few candidates, frequent failures , 2014, Alzheimer's Research & Therapy.

[8]  D. Matthews,et al.  Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study , 2013, Diabetes, obesity & metabolism.

[9]  Bruno Vellas,et al.  Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer’s disease clinical trials , 2013, Alzheimer's & Dementia.

[10]  J. Schneider,et al.  Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. , 2012, The Journal of clinical investigation.

[11]  C. Hölscher,et al.  Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice , 2012, Neurobiology of Aging.

[12]  Cindee M. Madison,et al.  Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI , 2011, Neurobiology of Aging.

[13]  Christian Hölscher,et al.  The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease , 2011, The Journal of Neuroscience.

[14]  C. Hölscher,et al.  Novel GLP‐1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain , 2011, Journal of neuroscience research.

[15]  C. Hölscher,et al.  LIRAGLUTIDE, A NOVEL GLP-1 ANALOGUE, PREVENTS THE IMPAIRMENT OF LEARNING AND LTP AND PLAQUE FORMATION IN AN APP/PS-1 MOUSE MODEL OF ALZHEIMER'S DISEASE , 2011 .

[16]  S. Minoshima,et al.  Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. , 2011, Archives of neurology.

[17]  A. Hofman,et al.  Insulin metabolism and the risk of Alzheimer disease , 2010, Neurology.

[18]  R. Pollom,et al.  Liraglutide in clinical practice: dosing, safety and efficacy , 2010, International journal of clinical practice. Supplement.

[19]  D. Moher,et al.  CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials , 2010, Journal of pharmacology & pharmacotherapeutics.

[20]  Rosemary O’Connor,et al.  Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling , 2010, Neurobiology of Aging.

[21]  S. Kalra,et al.  Liraglutide-A Novel GLP-1 Analogue , 2009 .

[22]  L. Blonde,et al.  The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1–5 studies , 2009, Diabetes, obesity & metabolism.

[23]  C. Hölscher,et al.  Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system , 2009, Neuroreport.

[24]  F. Hu,et al.  A profile of impaired insulin degradation in relation to late‐life cognitive decline: A preliminary investigation , 2009, International journal of geriatric psychiatry.

[25]  D. Matthews,et al.  Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes , 2008, Diabetes Care.

[26]  P. Mehta,et al.  Intranasal insulin improves cognition and modulates β-amyloid in early AD , 2008, Neurology.

[27]  Christian Hölscher,et al.  Common pathological processes in Alzheimer disease and type 2 diabetes: A review , 2007, Brain Research Reviews.

[28]  D. Selkoe,et al.  Soluble Aβ Inhibits Specific Signal Transduction Cascades Common to the Insulin Receptor Pathway* , 2007, Journal of Biological Chemistry.

[29]  J. Wands,et al.  Insulin and insulin-like growth factor resistance with neurodegeneration in an adult chronic ethanol exposure model. , 2007, Alcoholism, clinical and experimental research.

[30]  J. Frias,et al.  Incretins and their role in the management of diabetes , 2007, Current opinion in endocrinology, diabetes, and obesity.

[31]  P. Scheltens,et al.  Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.

[32]  A. Sima,et al.  Alzheimer-Like Changes in Rat Models of Spontaneous Diabetes , 2007, Diabetes.

[33]  A. Kirk.  Target Symptoms and Outcome Measures: Cognition , 2007, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[34]  N. Greig,et al.  Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease. , 2005, Current Alzheimer research.

[35]  Werner A. Scherbaum,et al.  Insulin and the CNS: effects on food intake, memory, and endocrine parameters and the role of intranasal insulin administration in humans , 2004, Physiology & Behavior.

[36]  P. Flatt,et al.  Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid. , 2004, Archives of biochemistry and biophysics.

[37]  D. Alkon,et al.  Insulin and the insulin receptor in experimental models of learning and memory. , 2004, European journal of pharmacology.

[38]  S. Craft,et al.  Modulation of memory by insulin and glucose: neuropsychological observations in Alzheimer's disease. , 2004, European journal of pharmacology.

[39]  S. Hoyer.  Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. , 2004, European journal of pharmacology.

[40]  A. Aleman,et al.  Insulin-like growth factor-I, cognition and brain aging. , 2004, European journal of pharmacology.

[41]  I. Torres-Aleman,et al.  The role of insulin and insulin-like growth factor I in the molecular and cellular mechanisms underlying the pathology of Alzheimer's disease. , 2004, European journal of pharmacology.

[42]  R. Rizza,et al.  Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans , 2003, Diabetologia.

[43]  W. Banks,et al.  Glucagon-like peptide-1 receptor is involved in learning and neuroprotection , 2003, Nature Medicine.

[44]  M. Mattson,et al.  Glucagon‐like peptide‐1 decreases endogenous amyloid‐β peptide (Aβ) levels and protects hippocampal neurons from death induced by Aβ and iron , 2003 .

[45]  N. Greig,et al.  A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. , 2002, The Journal of pharmacology and experimental therapeutics.

[46]  Jie Zhou,et al.  Glucagon-Like Peptide-1 Induces Cell Proliferation and Pancreatic-Duodenum Homeobox-1 Expression and Increases Endocrine Cell Mass in the Pancreas of Old, Glucose-Intolerant Rats. , 2000, Endocrinology.

[47]  P. J. Larsen,et al.  Distribution of GLP‐1 Binding Sites in the Rat Brain: Evidence that Exendin‐4 is a Ligand of Brain GLP‐1 Binding Sites , 1995, The European journal of neuroscience.

[48]  C. Jack,et al.  Framework : Towards a Biological Definition of Alzheimer ’ s Disease 1 2 draft 9-19-17 3 4 5 , 2017 .

[49]  D. Moher,et al.  Correspondence2010 Statement: updated guidelines for reporting parallel group randomised trials , 2010 .

[50]  G. Schellenberg,et al.  Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. , 2008, Journal of Alzheimer's disease : JAD.

[51]  C. Hölscher.  Development of Beta-Amyloid-induced Neurodegeneration in Alzheimer's Disease and Novel Neuroprotective Strategies , 2005, Reviews in the neurosciences.

[52]  M. Mattson,et al.  Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. , 2003, Journal of neuroscience research.

[53]  M. Sano,et al.  An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimer's Disease , 1997, Alzheimer disease and associated disorders.